Header Logo

Connection

GEORGE CHOLANKERIL to Carcinoma, Hepatocellular

Back to Details
This is a "connection" page, showing publications GEORGE CHOLANKERIL has written about Carcinoma, Hepatocellular.
GEORGE CHOLANKERIL
Connection Strength
5.140
Carcinoma, Hepatocellular
  1. Inequalities in Developing Cirrhosis Complications Over Time: A Cohort Study. Am J Gastroenterol. 2025 Nov 01; 120(11):2548-2558.
    View in: PubMed
    Score: 0.468
  2. Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea". J Hepatol. 2024 05; 80(5):e218-e219.
    View in: PubMed
    Score: 0.436
  3. Survival following liver transplantation for hepatocellular carcinoma after implementation of MMaT-3 policy. Liver Transpl. 2023 10 01; 29(10):1138-1142.
    View in: PubMed
    Score: 0.414
  4. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era. Clin Gastroenterol Hepatol. 2023 08; 21(9):2288-2297.e4.
    View in: PubMed
    Score: 0.403
  5. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.401
  6. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2023 02; 43(1):89-99.
    View in: PubMed
    Score: 0.398
  7. Comparable Survival for Hepatitis C-Related Hepatocellular Carcinoma After Liver Transplantation Irrespective of Viremic Status. Clin Gastroenterol Hepatol. 2023 05; 21(5):1362-1364.e1.
    View in: PubMed
    Score: 0.384
  8. NAFLD and HCC: Time to Bridge the Gap. Hepatology. 2021 11; 74(5):2336-2338.
    View in: PubMed
    Score: 0.369
  9. Disparities in Liver Transplantation Resulting From Variations in Regional Donor Supply and Multiple Listing Practices. Clin Gastroenterol Hepatol. 2017 02; 15(2):313-315.
    View in: PubMed
    Score: 0.261
  10. Evolving burden of metabolic dysfunction-associated steatotic liver disease and its complications in a US nationwide healthcare system. Hepatol Commun. 2026 Jan 01; 10(1).
    View in: PubMed
    Score: 0.125
  11. Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018-2023. Clin Mol Hepatol. 2024 Oct; 30(4):756-770.
    View in: PubMed
    Score: 0.112
  12. Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin Mol Hepatol. 2024 Jul; 30(3):436-448.
    View in: PubMed
    Score: 0.111
  13. Impact of the COVID-19 pandemic on hospitalizations with hepatocellular carcinoma in the United States. Expert Rev Gastroenterol Hepatol. 2024 Jan-Feb; 18(1-3):113-119.
    View in: PubMed
    Score: 0.109
  14. Exposure to Agent Orange and Hepatocellular Carcinoma Among US Military Personnel. JAMA Netw Open. 2023 12 01; 6(12):e2346380.
    View in: PubMed
    Score: 0.108
  15. Trends in mortality of liver cancer before and during the COVID-19 pandemic, 2017-2021. Liver Int. 2023 09; 43(9):1865-1870.
    View in: PubMed
    Score: 0.105
  16. Disparities in hepatocellular carcinoma survival by Medicaid-status: A national population-based risk analysis. Eur J Surg Oncol. 2023 04; 49(4):794-801.
    View in: PubMed
    Score: 0.101
  17. Is Liver Transplant Justified at Any MELD Score? Transplantation. 2023 03 01; 107(3):680-692.
    View in: PubMed
    Score: 0.100
  18. Changing trends in aetiology-based hospitalizations with end-stage liver disease in the United States from 2016 to 2019. Liver Int. 2022 11; 42(11):2390-2395.
    View in: PubMed
    Score: 0.099
  19. Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation. Clin Gastroenterol Hepatol. 2023 08; 21(9):2410-2412.e1.
    View in: PubMed
    Score: 0.098
  20. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.098
  21. DETECT: Development of Technologies for Early HCC Detection. Gastroenterology. 2022 07; 163(1):21-27.
    View in: PubMed
    Score: 0.096
  22. Decline in Annual Mortality of Hepatitis C Virus-Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. Gastroenterology. 2020 10; 159(4):1558-1560.e2.
    View in: PubMed
    Score: 0.084
  23. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. Liver Int. 2019 09; 39(9):1661-1671.
    View in: PubMed
    Score: 0.079
  24. Hepatocellular carcinoma is leading in cancer-related disease burden among hospitalized baby boomers. Ann Hepatol. 2019 Sep - Oct; 18(5):679-684.
    View in: PubMed
    Score: 0.079
  25. Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. Hepatology. 2019 03; 69(3):1064-1074.
    View in: PubMed
    Score: 0.077
  26. Cost of Care for Patients With Cirrhosis. Am J Gastroenterol. 2024 03 01; 119(3):497-504.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.